News
Market Trends, Business Strategies, Competitive Intelligence, Clinical Trials, and Patent Trends Driving Growth from 2024 to 2029"Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest ...
During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...
Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial, highlighting the long-term efficacy and durability of ciltacabtagene autoleucel in multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results